56results about How to "Enhance antigen presentation" patented technology

The present invention provides bacterial immunogenic agents for administration to humans and non-human animals to stimulate an immune response. It particularly relates to the vaccination of mammalian species, especially human patients, with variants of the E. coli FimCH protein that elicit antibodies that have better functional inhibitory activity than antibodies raised against wild type protein. In particular, such variants include mutations that promote a more open confirmation of the FimH protein, particularly in regions involved in mannose binding, to expose regions previously poorly exposed and mutations that abolish a significantly reduce mannose binding. In another aspect, the invention provides antibodies against such proteins and protein complexes that may be used in passive immunization to protect or treat pathogenic bacterial infections. The present invention also provides machine readable media embedded with the three-dimensional atomic structure coordinates of FimCH bound to mannose, and subsets thereof, and methods of using the crystal structure to provide candidate amino acid residues for mutation.

The invention relates generally to the treatment and prevention of human cancer and viral diseases. More specifically, this invention relates to development of a new generation of vaccines that rely on eliciting cellular immune responses, specifically induction of cytotoxic T lymphocytes (CTL), against cancer cells and virus-infected cells via administration of a polymeric nanoparticle containing a vaccine comprising a fusion peptide or a modified peptide. Such a fusion peptide is composed of an insertion signal sequence and a peptide derived from a tumor antigen or a viral antigen, which improves antigen presentation and induces CTL with higher efficiency against cancer cells and virus-infected cells. An exemplary peptide utilized in the invention is Mart-1:27-35 peptide.

Molecular conjugates comprising an antigen linked to a human monoclonal antibody that specifically binds to dendritic cells are disclosed. Also disclosed are pharmaceutical compositions comprising the molecular conjugates and therapeutic methods for using the conjugates.

Compositions and methods of producing vaccines, including methods wherein whole organism vaccines are provided with limited replication abilities, thereby increasing vaccine safety and efficacy, through the use of non-natural, unnatural, or non-naturally encoded amino acids.

An immunotherapeutic strategy is disclosed that combines antigen-encoding DNA vaccine compositions combined with siRNA directed to pro-apoptotic genes, primarily Bak and Bax, the products of which are known to lead to apoptotic death. Gene gun delivery (particle bombardment) of siRNA specific for Bak and/or Bax to antigen-expressing DCs prolongs the lives of such DCs and lead to enhanced generation of antigen-specific CD8+ T cell-mediated immune responses in vivo. Similarly, antigen-loaded DC's transfected with siRNA targeting Bak and/or Bax serve as improved immunogens and tumor immunotherapeutic agents.

The invention relates to the field of veterinary biological products and is aimed at providing a veterinary vaccine immunologic adjuvant as well as a preparation and application method thereof. The adjuvant is prepared by mixing water-soluble calcium carbonate, polysorbate 80, 2-phenoxy ethanol, chitosan oligosaccharide, xanthan gum and deionized water, wherein the weight ratio of the water-soluble calcium carbonate to deionized water is 0.001-0.01%; the volume ratio of the polysorbate 80 to deionized water is 1-10%; the final concentration of the 2-phenoxy ethanol is 0.5-2.5% (volume ratio); the final concentration of the chitosan oligosaccharide is 0.5-2% (weight ratio); the final concentration of the xanthan gum is 0.1-2% (weight ratio). The adjuvant provided by the invention can enhance the identification ability of lymphocytes for the A, B and H antigens, promote the combination of multiple antigens with an antibody and enhance the immune response level and antigen presentation ability. The adjuvant is kept in a steady state at low temperature and room temperature; due to the antibacterial ability, secondary infection after immunization is avoided. The adjuvant is easy to prepare and thus can be stored for long time at room temperature. The cost of raw materials is low, and the adjuvant is suitable for large-area promotion and application.

The present inventors worked on elucidating the mechanism of antigen cross-presentation by dendritic cells, and revealed that foreign antigens taken up in dendritic cells are degraded by proteasomes after undergoing polyubiquitination. Based on the novel finding that polyubiquitination is involved in cross-presentation, the promotion of polyubiquitination was attempted by a number of methods, and the promotion of antigen presentation was confirmed. These methods enable the production of dendritic cells effective for inducing CTL activation.

The invention relates to a preparation method and an application of efficient immunocompetent cell CpG-DCIK. The preparation method comprises the following steps: inducing DC cell by use of CpG and cytokine, inducing homologous CIK cell by use of cytokine, and performing mixed culture of the DC cell and CIK cell to obtain a new immune effector cell population, namely oligonucleotide induced dendritic cell and cytokine induced killer cell co-culture cell which is named CpG-DCIK. According to the invention, the DC is induced by use of in-vitro CpG-ODN in combination with cytokine, and then the DC is co-cultured with homologous CIK to obtain an immune effector cell population with higher proliferation activity and cytotoxic activity, and an immune cell population with relatively high antitumor activity can still be induced and amplified for the cases in which a tumor antigen is hardly acquired since the operation opportunity is lost or the cancer is in the late stage and the like, thereby widening the application range of tumor resistance.

The invention discloses Artocarpus lingnanensis lectin capable of inducing dentritic cells (DC) to mature and proliferate in vitro, a special culture medium for inducing DC to mature and proliferate, and a preparation method for the DC. The Artocarpus lingnanensis lectin is prepared from red cassia tree seeds through separation and purification by the conventional separation method. According to the special culture medium, inducing factors and the Artocarpus lingnanensis lectin are added into a DC culture medium. The preparation method comprises the following steps: adding precursor cells of the DC and the inducing factors into the DC culture medium, and adding the Artocarpus lingnanensis lectin when the cells are cultured in the sixth day; and continuously culturing to obtain mature DC, wherein the precursor cells are peripheral blood mononuclear cells; and the inducing factors are granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4). A stable culture technical system for inducing the DC to mature and proliferate is established, and is easy to operate, convenient and practical; the required cell factors are a few, and the cost is low; and the dentritic cells (DC) have high maturity and strong functions. The Artocarpus lingnanensis lectin provides a novel effective way for further developing vaccine enhancers.

The invention relates to the technical field of cell culture, and in particular relates to a DC cell culture reagent and a culture method thereof. The DC cell culture reagent includes a first DC cell culture reagent and a second DC cell culture reagent, wherein the first DC cell culture reagent consists of GM-SCF and IL-4; and the second DC cell culture reagent consists of GM-SCF, IL-4, TNF-alpha and MDC. The method disclosed by the invention, by improving the type and the concentration of cell factors in a DC cell culture process, can be used for promoting the proliferation in the quantity of DC cells and keeping a relatively good cell viability, so that the antigen presentation capacity of the DC cells is enhanced and a better antitumor effect is guaranteed.

The invention provides a gingseng extract product FQR1 as well as a preparation and an application thereof, and provides a FQR1 induced culture method for DC-CIK cell. The method comprises the following steps: a collection of peripheral blood, an acquisition of tumor antigens, a separation of mononuclear cells, a washing, an induction of DC-CIK cells, a culture, etc. The obtained gingseng extract product FQR1 can effectively increase propagation of DC-CIK cells, improve tumor killing activity of DC-CIK cells, and prolong the survival time with tumor of tumor-bearing mice with the DC-CIK cell therapy.

The present invention provides methods for stimulating an immune response to an antigen comprising administering to an individual, an anucleate cell-derived vesicle comprising an antigen and/or an adjuvant. In some embodiments, the anucleate cell-derived vesicle comprising the antigen and/or adjuvant is generated by passing a cell suspension containing an input anucleate cell through a constriction, wherein the constriction deforms the input anucleate cell thereby causing a perturbation of the cell to form an anucleate cell-derived vesicle such that an antigen and/or an adjuvant enters the anucleate cell-derived vesicle. In some embodiments, the anucleate cell-derived vesicle comprising the antigen and/or adjuvant is delivered to an individual and the antigen is delivered to and processed in an immunogenic environment to treat a disease, prevent a disease, and/or vaccinate an individual against an antigen.

Whole-cell vaccines and methods for their use in producing protective immune responses in vertebrate hosts subsequently exposed to pathogenic bacteria. The present invention involves a method of enhancing antigen presentation by intracellular bacteria in a manner that improves vaccine efficacy. After identifying an enzyme that has an anti-apoptotic effect upon host cells infected by an intracellular microbe, the activity of the enzyme is reduced, thereby modifying the microbe so that it increases immunogenicity. Also, the present invention provides a method of incrementally modifying enzyme activity to produce incrementally attenuated mutants of the microbe from which an effective vaccine candidate can be selected.

The current disclosure describes the use of NFkB inhibitors as immune potentiators in vaccine compositions comprising adjuvants. Accordingly, aspects of the disclosure relate to a method for vaccinating a subject comprising administering a NFkB inhibitor and an adjuvant (or a composition of the disclosure comprising NFkB and an adjuvant) to the subject. Further aspects relate to a method for inhibiting an inflammatory reaction associated with an adjuvant in a subject, the method comprising co-administering a NFkB inhibitor and an adjuvant (or a composition of the disclosure comprising NFkB and an adjuvant) to the subject. Yet further aspects relate to a pharmaceutical composition comprising a NFkB inhibitor and an adjuvant.

The present invention relates to a DC inducer, comprising: rhGM-CSF, GM-CSF, IL-4, rhIL-4 and IL-13. The present invention further relates to the application of the above-mentioned DC inducer in the process of inducing DC maturation. Compared with the prior art, the DC inducer provided by the present invention can increase the cell activity of dendritic cells, increase the proliferation rate and maturation rate of dendritic cells, and further improve the antigen presentation of dendritic cells.